Financial PerformanceSteady financial results and new license agreements are factors in maintaining a Buy rating for the stock, with a price target representing over 100% potential share price appreciation.
Pipeline ProgressOmniAb has added new discovery licenses and increased its roster of active programs, indicating strong growth and development.
Research And DevelopmentAnalyst maintains a Buy rating on OABI shares due to the long-term potential of the Company's broad partnered R&D pipeline.